Introduction
Human normal immunoglobulin (formerly known as gammaglobulin) has been given for many years to persons who have come into contact with infectious hepatitis, or to those liable to come into contact with the disease, in the hope of preventing infection.
Many studies of the protection conferred by American immunoglobulin have been made following the observations of its efficacy by Stokes & Neefe in 1945 . Notable among these were the investigations carried out at the Willowbrook State School and described by Krugman (1963) . Immunoglobulin was given to 635 children newly admitted to this mental institution where infectious hepatitis was endemic; during the first 6 months after inoculation only one case of jaundice occurred in this treated group compared with thirty-one cases in a control group of untreated children.
These studies left little doubt that the American product gives a large degree of protection against the clinical manifestations of the disease. During the follow-up period eighteen cases of infectious hepatitis occurred among those given immunoglobulin and sixty cases were reported among the controls (Table 1) . However, if the cases that occurred during the first 2 weeks after injection were excluded (because they were probably incubating the disease when injected) only six inoculated persons developed the disease compared with fortysix persons in the control group. This investigation demonstrates therefore, that immunoglobulin of British origin is an effective measure against the development of the clinical manifestations of infectious hepatitis among contacts. However, although suppressing the overt features of the disease, there is evidence (Ward & Krugman, 1962 work in countries where the chance of acquiring hepatitis would be expected to be higher than in Britain.
Since July 1965 a single dose of 750 mg (5.1 ml) of immunoglobulin has been given to each member about a week before departure from the United Kingdom and the dose has not been repeated during their stay overseas. It was therefore possible to compare the frequency of infectious hepatitis among the inoculated members with that in those who went abroad during the year before immunoglobulin was made available. Of the inoculated members of VSO only one case of infectious hepatitis occurred during the first 7 months after receiving immunoglobulin (Table 2) and he became ill within a week of inoculation. After the seventh month, however, cases began to appear in the inoculated group. In contrast, among those who were not given immunoglobulin, infectious hepatitis began to occur during the second month abroad. Thus a single dose of 750 mg appears to be effective for a period of up to 7 months after inoculation.
Immunoglobulin for the prevention of serum hepatitis
The evidence of the value of immunoglobulin for the prevention of serum hepatitis is conflicting. Grossman, Stewart & Stokes (1945) reported that 11 5 % of battle casualties who had been given blood transfusions became jaundiced compared with only 2.9% of those who had also received 10 ml of immunoglobulin.
More recently, however, studies by Krugman & Giles (1970) have cast doubt on the usefulness of immunoglobulin for contacts of serum hepatitis. Mixtures of immunoglobulin and serum from patients suffering from serum hepatitis were given to fourteen children and ten developed the disease (Table 3) . Of eight other children who were given 
